Altimmune, Inc. (ALT) vs CytomX Therapeutics, Inc. (CTMX)
A side-by-side comparison of Altimmune, Inc. and CytomX Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CTMX
CytomX Therapeutics, Inc.
$2.58HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALT vs CTMX
growth of $100 · dividends reinvested · last 9yALT -98.0% (-35.2%/yr)CTMX -82.0% (-17.3%/yr)CTMX compounded faster over this window
Log scale — wide-divergence pair
ALT CTMX
ALT vs CTMX: by the numbers
- •CTMX is the larger company ($562M vs $519M market cap).
- •Both run net losses; CTMX's is the smaller (-435.21% vs -296000.00% net margin).
- •CTMX grew revenue faster over the past five years (2.18% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | CTMX |
|---|---|---|
| P/S ratio | 16749.86 | 30.69 |
| P/B ratio | 1.09 | 1.86 |
Profitability
| Metric | ALT | CTMX |
|---|---|---|
| Gross margin | 100.00% | 98.63% |
| Operating margin | -230460.98% | -29.35% |
| Net margin | -296000.00% | -435.21% |
| ROE | -19.35% | -26.37% |
| ROIC | -19.47% | -25.42% |
Growth (annualized)
| Metric | ALT | CTMX |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 2.18% |
| Total return CAGR (5Y) | -25.30% | -12.01% |
Frequently asked
- Which has grown faster, ALT or CTMX?
- Over the past five years, CTMX grew revenue faster — ALT at a -65.38% CAGR versus CTMX at 2.18%.
- How have ALT and CTMX total returns compared?
- Over the past 5 years, ALT delivered -25.30% and CTMX delivered -12.01% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.